Advertisement

---

OMEROS CORPORATION

European Medicines Agency Approves Positive Opinion on Omeros' Pediatric Investigation Plan for OMS302

[2013-07-02] - -- Submission of Marketing Authorization Application Remains on Track for Mid-Year--


Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program

[2013-06-13] - -- Enrollment Expected to Begin Next Month --


Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial

[2013-05-31] - -- OMS824 Achieves High Target Occupancy without Causing Movement Disorders Seen with Other PDE10 Inhibitors --


Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program

[2013-05-28] - -- Phase 1 Clinical Trial Expected to Begin Early Next Quarter --


Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease

[2013-05-23] - -- Clinical Trial in Patients with Huntington's Disease Slated to Begin Next Quarter --


Omeros to Present at Two Upcoming Conferences

[2013-05-22] -


Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock

[2013-05-14] -


Omeros Corporation Reports First Quarter 2013 Financial Results

[2013-05-10] -


Omeros Announces $16.2 Million Registered Direct Offering of Common Stock

[2013-05-09] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers